What is KZIA's current stock price?

KZIA (Kazia Therapeutics Limited) is currently trading at $13.66 with a market cap of $22.1M.

What sector is Kazia Therapeutics Limited in?

Kazia Therapeutics Limited (KZIA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is KZIA a good stock to buy?

Analysts have a Buy consensus on KZIA with a price target of $21.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

KZIA Kazia Therapeutics Limited

Healthcare

$13.66+3.72%ClosedMarket Cap: $22.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.28

P/S

1565.80

EV/EBITDA

2.12

DCF Value

$-0.59

FCF Yield

-29.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-92086.4%

Net Margin

-113004.6%

ROE

-116.9%

ROA

-31.4%

ROIC

-36.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$0.00	$-12.3M	$—
Q4 null	$19.7K	$-10.0M	$—
FY null	$42.0K	$-20.7M	$—
Q2 null	$22.3K	$-10.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$21.50

Target (Median)

$21.50

Target Range

$18.00 - $25.00

2 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-01-28

HC Wainwright & Co.Buy

2025-12-12

Maxim GroupBuy

2025-10-02

HC Wainwright & Co.Buy

2025-07-10

Maxim GroupBuy

2025-06-11

Trading Activity

Insider Trades

View All

Rao Sudhaofficer

SellTue May 19

Friend John E. IIofficer: Chief Executive Officer

SellThu Apr 09

Cain Davidofficer: Director, CMC

SellWed Apr 01

Cain Davidofficer: Director, CMC

SellWed Apr 01

Cain Davidofficer: Director, CMC

SellWed Apr 01

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.23

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Peers

GRI

INM